Sandoz to file for approval of aflibercept biosimilar
Sandoz intends to seek regulatory approval for its aflibercept biosimilar…
Sandoz intends to seek regulatory approval for its aflibercept biosimilar in the US and EU in the coming months.
List view / Grid view
Sandoz intends to seek regulatory approval for its aflibercept biosimilar…
Sandoz intends to seek regulatory approval for its aflibercept biosimilar in the US and EU in the coming months.
A planned investment of approximately $90 million will help build…
A planned investment of approximately $90 million will help build Sandoz’s new Slovenia-based biopharma biosimilar development facility by 2026.